Physician profile
Junior Pittack
NPI 1023053931
$11,056.99
in general payments reported to CMS, 2019-2025
24 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,109 · 2020: $2,079 · 2021: $661 · 2022: $1,117 · 2023: $1,860 · 2024: $1,061 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,090.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,853.57 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Lundbeck LLC | $1,371.96 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $1,101.80 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,080.32 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,078.59 | 2021-2025 | |
| Allergan, INC. | $849.26 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $543.55 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $479.91 | 2025 | Qelbree |
| Neurocrine Biosciences, INC. | $374.30 | 2019-2021 | |
| Corium, LLC | $332.67 | 2022-2024 | Azstarys |
| Indivior INC. | $322.13 | 2019-2020 | |
| Alkermes, INC. | $319.47 | 2019-2022 | |
| Neos Therapeutics, Lp | $238.16 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| Shire North American Group INC | $197.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $146.89 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $146.24 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $141.09 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $121.84 | 2022 | |
| Tris Pharma INC | $106.08 | 2023-2025 | Dyanavel Xr |
| Noven Pharmaceuticals, INC. | $97.49 | 2024 | Xelstrym |
| Vanda Pharmaceuticals INC. | $55.70 | 2019 | |
| Ironshore Pharmaceuticals INC. | $43.52 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $41.43 | 2025 | Cobenfy |
| Eisai INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junior Pittack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.